Use of glycopyrrolate for treating tachycardia
The invention relates to a novel use of the antimuscarinic agent glycopyrrolate, for example the salt glycopyrronium bromide. In particular, the invention relates to glycopyrrolate for use as a heart rate lowering agent and more particularly, but not exclusively, for use in patients suffering from respiratory conditions such as chronic obstructive pulmonary disease.
1. A method of treating tachycardia, in a patient having tachycardia, by reducing the patient's heart rate for a period of at least 0.75 hours, said method comprising administering to the patient, via inhalation, an effective amount of an inhalable pharmaceutical composition comprising glycopyrrolate or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1 , wherein the composition is administered to a patient suffering from a respiratory condition selected from chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis (CF) and related airway diseases.
3. The method, according to claim 2 , wherein the patient has COPD.
4. The method, according to claim 1 , wherein the patient has tachycardia that has been pharmaceutically induced.
5. The method, according to claim 4 , wherein the tachycardia has been induced by administration of salbutamol.
6. The method, according to claim 1 , wherein the patient has tachycardia that is induced by an endocrine disorder.
7. The method, according to claim 1 , wherein the patient has a form of tachycardia selected from the group consisting of ventricular tachycardia, supraventricular tachycardia, atrial fibrillation, AV nodal reentrant tachycardia (AVNRT), AV reentrant tachycardia (AVRT) and junctional tachycardia.
8. The method, according to claim 1 , wherein the patient has a resting heart rate of greater than 90 beats per minute.
9. The method, according to claim 1 , wherein the glycopyrrolate or a pharmaceutically acceptable salt thereof comprises glycopyrronium bromide.
10. The method, according to claim 1 , wherein glycopyrrolate is present within the composition in an amount of between 10 and 500 μg.
11. The method, according to claim 10 , wherein glycopyrrolate is present within the composition in an amount of 20 μg.
12. The method, according to claim 10 , wherein glycopyrrolate is present within the composition in an amount of 400 μg.
13. The method according to claim 1 , wherein the glycopyrrolate is administered once daily.
14. The method, according to claim 1 , wherein the pharmaceutical composition is formulated as a dry powder formulation.
15. The method, according to claim 1 , wherein the composition additionally comprises a force control agent.
16. The method, according to claim 15 , wherein the force control agent comprises a metal stearate, or a derivative thereof.
17. The method, according to claim 16 , wherein the force control agent comprises zinc stearate, magnesium stearate, calcium stearate, sodium stearate or lithium stearate.
18. The method, according to claim 17 , wherein the force control agent comprises magnesium stearate.
19. The method, according to claim 1 , wherein the composition further comprises lactose.
20. The method, according to claim 19 , wherein the composition comprises 1% (w/w) glycopyrronium bromide and 99% (w/w) lactose.
21. The method, according to claim 19 , wherein the composition comprises 1.05% (w/w) glycopyrronium bromide, 98.8% (w/w) lactose and 0.15% (w/w) magnesium stearate, or 1% (w/w) glycopyrronium bromide, 98.8% (w/w) lactose and 0.2% (w/w) magnesium stearate.
22. The method, according to claim 1 , wherein the composition further comprises indacaterol.
23. The method, according to claim 1 , wherein the composition further comprises a beta agonist.
24. The method, according to claim 1 , wherein the patient is receiving concomitant treatment with a beta agonist.
25. The method according to claim 1 , wherein the patient has been diagnosed with an increased heart rate.